Literature DB >> 23296434

Developmental function in toddlers with sickle cell anemia.

F Daniel Armstrong1, T David Elkin, R Clark Brown, Penny Glass, Sohail Rana, James F Casella, Ram V Kalpatthi, Steven Pavlakis, Zhibao Mi, Winfred C Wang.   

Abstract

BACKGROUND: Neurocognitive impairment occurs in children and adults with sickle cell anemia, but little is known about neurodevelopment in very young children. We examined the neurodevelopmental status of infants participating in the Pediatric Hydroxyurea Phase III Clinical Trial (Baby Hug) to determine relationships with age, cerebral blood flow velocity, and hemoglobin concentration.
METHODS: Standardized measures of infant neurodevelopment were administered to 193 infants with hemoglobin SS or hemoglobin S-β(0) thalassemia between 7 and 18 months of age at the time of their baseline evaluation. Associations between neurodevelopmental scores and age, family income, parent education, hemoglobin concentration, and transcranial Doppler velocity were examined.
RESULTS: Mean functioning on the baseline neurodevelopment scales was in the average range. There were no mental development scores <70 (impaired); 22 children had scores in the clinically significant range, 11 with impaired psychomotor scores and 11 with problematic behavior rating scores. Significantly poorer performance was observed with older age at baseline. Behavior rating scores were an average of 2.82 percentile points lower per month of age, with similar patterns observed with parent report using adaptive behavior scales. Parent-reported functional abilities and hemoglobin were negatively associated with higher transcranial Doppler velocities.
CONCLUSIONS: Whereas overall functioning was in the normal range, behavioral and adaptive function was poorer with older age, even in this very young group of children. Explanatory mechanisms for this association between poorer developmental function and older age need to be identified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296434      PMCID: PMC3557401          DOI: 10.1542/peds.2012-0283

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  23 in total

1.  Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation.

Authors:  F Bernaudin; S Verlhac; F Fréard; F Roudot-Thoraval; M Benkerrou; I Thuret; R Mardini; J P Vannier; E Ploix; M Romero; C Cassé-Perrot; M Helly; E Gillard; G Sebag; H Kchouk; J P Pracros; B Finck; J N Dacher; V Ickowicz; C Raybaud; M Poncet; E Lesprit; P H Reinert; P Brugières
Journal:  J Child Neurol       Date:  2000-05       Impact factor: 1.987

2.  Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.

Authors:  Mark T Gladwin; James H Shelhamer; Frederick P Ognibene; Margaret E Pease-Fye; James S Nichols; Beth Link; Daksesh B Patel; Marcin A Jankowski; Lewis K Pannell; Alan N Schechter; Griffin P Rodgers
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

3.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

4.  Design of the silent cerebral infarct transfusion (SIT) trial.

Authors:  James F Casella; Allison A King; Bruce Barton; Desiree A White; Michael J Noetzel; Rebecca N Ichord; Cindy Terrill; Deborah Hirtz; Robert C McKinstry; John J Strouse; Thomas H Howard; Thomas D Coates; Caterina P Minniti; Andrew D Campbell; Bruce A Vendt; Harold Lehmann; Michael R Debaun
Journal:  Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.969

5.  Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease.

Authors:  W Wang; L Enos; D Gallagher; R Thompson; L Guarini; E Vichinsky; E Wright; R Zimmerman; F D Armstrong
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

6.  Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia.

Authors:  Elliott P Vichinsky; Lynne D Neumayr; Jeffrey I Gold; Michael W Weiner; Randall R Rule; Diana Truran; Jeffrey Kasten; Barry Eggleston; Karen Kesler; Lillian McMahon; Eugene P Orringer; Thomas Harrington; Karen Kalinyak; Laura M De Castro; Abdullah Kutlar; Cynthia J Rutherford; Cage Johnson; Joel David Bessman; Lanetta B Jordan; F Daniel Armstrong
Journal:  JAMA       Date:  2010-05-12       Impact factor: 56.272

7.  Detection and assessment of stroke in patients with sickle cell disease: neuropsychological functioning and magnetic resonance imaging.

Authors:  Jeffrey I Gold; Caroline B Johnson; Marsha J Treadwell; Nitu Hans; Elliott Vichinsky
Journal:  Pediatr Hematol Oncol       Date:  2008-06       Impact factor: 1.969

8.  MRI abnormalities of the brain in one-year-old children with sickle cell anemia.

Authors:  Winfred C Wang; Steven G Pavlakis; Kathleen J Helton; Robert C McKinstry; James F Casella; Robert J Adams; Renee C Rees
Journal:  Pediatr Blood Cancer       Date:  2008-11       Impact factor: 3.167

9.  Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Authors:  Steven G Pavlakis; Renée C Rees; Xiangke Huang; R Clark Brown; James F Casella; Rathi V Iyer; Ram Kalpatthi; Judy Luden; Scott T Miller; Zora R Rogers; Courtney D Thornburg; Winfred C Wang; Robert J Adams
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

10.  The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

Authors:  Bruce W Thompson; Scott T Miller; Zora R Rogers; Renee C Rees; Russell E Ware; Myron A Waclawiw; Rathi V Iyer; James F Casella; Lori Luchtman-Jones; Sohail Rana; Courtney D Thornburg; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada Sarnaik; Thomas H Howard; Lori Luck; Winfred C Wang
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

View more
  18 in total

Review 1.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

Review 2.  Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease.

Authors:  Eboni I Lance; James F Casella; Allen D Everett; Emily Barron-Casella
Journal:  Proteomics Clin Appl       Date:  2014-11-06       Impact factor: 3.494

3.  Cognitive and behavior deficits in sickle cell mice are associated with profound neuropathologic changes in hippocampus and cerebellum.

Authors:  Li Wang; Luis E F Almeida; Celia M de Souza Batista; Alfia Khaibullina; Nuo Xu; Sarah Albani; Kira A Guth; Ji Sung Seo; Martha Quezado; Zenaide M N Quezado
Journal:  Neurobiol Dis       Date:  2015-10-14       Impact factor: 5.996

Review 4.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03

5.  Developmental Screening in Pediatric Sickle Cell Disease: Disease-Related Risk and Screening Outcomes in 4 Year Olds.

Authors:  Jeffrey Schatz; Alyssa Schlenz; Laura Reinman; Kelsey Smith; Carla W Roberts
Journal:  J Dev Behav Pediatr       Date:  2017-10       Impact factor: 2.225

6.  A pilot study of parent education intervention improves early childhood development among toddlers with sickle cell disease.

Authors:  Melanie E Fields; Catherine Hoyt-Drazen; Regina Abel; Mark J Rodeghier; Janet M Yarboi; Bruce E Compas; Allison A King
Journal:  Pediatr Blood Cancer       Date:  2016-08-11       Impact factor: 3.167

Review 7.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Sarah J Nevitt; Ashley P Jones; Jo Howard
Journal:  Cochrane Database Syst Rev       Date:  2017-04-20

8.  Sociodemographic and Biomedical Correlates of Developmental Delay in 2- and 4-Year-Olds with Sickle Cell Disease.

Authors:  Jeffrey Schatz; Laura Reinman; Sarah E Bills; Julia D Johnston
Journal:  J Dev Behav Pediatr       Date:  2021-09-24       Impact factor: 2.988

9.  Pediatric Neurodevelopmental Delays in Children 0 to 5 Years of Age With Sickle Cell Disease: A Systematic Literature Review.

Authors:  La'Kita M J Knight; Allison A King; John J Strouse; Paula Tanabe
Journal:  J Pediatr Hematol Oncol       Date:  2021-04-01       Impact factor: 1.289

10.  Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.

Authors:  Andrew M Heitzer; Jennifer Longoria; Victoria Okhomina; Winfred C Wang; Darcy Raches; Brian Potter; Lisa M Jacola; Jerlym Porter; Jane E Schreiber; Allison A King; Guolian Kang; Jane S Hankins
Journal:  Br J Haematol       Date:  2021-07-16       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.